Neutral
●
GlobeNewsWire
●
6 months ago
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its first quarter 2026 financial results and operational highlights before open of U.S. markets on Thursday, May 14,...